Neuvasq Biotechnologies appoints Denis Bedoret as Executive Director

Neuvasq Biotechnologies, a privately held biotech company based in Gosselies (Belgium) dedicated to advancing pioneering therapies to restore CNS blood barriers in patients withophthalmologic and neurologic conditions, is announcing the appointment of Denis Bedoret as Executive Director.

Denis Bedoret is bringing more than 10 years of experience of leadership at various Biotech firms as well as a member of Boards of Director of several public and private life sciences companies.

“We are delighted to welcome Denis as Executive Director. As he has been a member of Neuvasq Board for the last two years, he already has an extensive knowledge of the company, in addition to a broad experience in the biotech industry. Therefore, he should be able to quickly unlock all the potential of Neuvasq assets in the various diseases where it can bring the best value for patients” said Michel Allé, Chairman of the Board.

About Neuvasq Biotechnologies

Neuvasq Biotechnologies, a privately held biotech company, has been initiated as a spin-off of the laboratory of Prof. Benoît Vanhollebeke (Universté Libre de Bruxelles) and is dedicated to advancing pioneering therapies to restore CNS barriers and improve neurovascular function for patients with severe conditions. Neuvasq’s most advanced programs aim to address the breakdown of the blood-retinal barrier (BRB) and improve vision in patients with vascular retinopathy conditions such as diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). In addition, Neuvasq is exploring novel solutions to address blood-brain barrier (BBB) breakdown and neurovascular impairment in diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke, and/or epilepsy. The company is headquartered in Gosselies, Belgium.